Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease

Frontiers in Pediatrics

article

Yoshihiro Azuma¹  Kiyoshi Ichihara²  Shouichi Ohga¹  Shunji Hasegawa¹  Yasuo Suzuki¹  Seigo Okada¹  Chie Matsuguma¹  Hiroyuki Wakiguchi¹  Yuji Ohnishi¹  Takashi Furuta¹  Akiko Miyake¹  Hiroki Yasudo¹ 

[1] Department of Pediatrics, Yamaguchi University Graduate School of Medicine;Department of Laboratory Sciences, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine;Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University

关键词: intravenous immunoglobulin;    Kawasaki disease;    macrophage;    soluble CD163;    sCD163;   

DOI  :  10.3389/fped.2020.00148

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Objective: Intravenous immunoglobulin (IVIG) therapy is a useful first-line treatment for Kawasaki disease (KD); however, 10–20% of patients fail to respond and require additional IVIG. Soluble CD163 (sCD163) is considered a biomarker for macrophage activation. There are no reports measuring serum sCD163 in KD patients. This study aimed to explore its possible utility in the clinical management of patients with KD. Methods: Eighty-seven patients with well-defined KD were retrospectively enrolled together with 19 healthy individuals with comparable ages. KD patients were classified into three groups, Group A (initial IVIG responders), Group B (additional IVIG responders), and Group C (additional IVIG non-responders). Serum sCD163 together with complete blood counts, C-reactive protein, d-dimer, albumin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured before the initial IVIG treatment in all cases, and afterward in a fraction of cases. Results: Serum sCD163 in KD patients before initial IVIG was generally much higher than the control group. The median (interquartile range) of sCD163 was as follows: Control 446 (385–521) ng/mL; Group A, 699 (478–1,072); Group B, 1,349 (1,116–1,390); and Group C, 665 (544–1,094). In general, sCD163 showed close positive correlation with ALT and AST, but none with other markers. Among the KD groups, Group B showed the highest sCD163: Group B vs. A: p = 0.0003; B vs. C: p = 0.035). Serum sCD163 was significantly increased after IVIG in Group A, while no change occurred in others. Conclusion: The serum sCD163 levels could be a useful biomarker in the clinical management of KD, especially for predicting responsiveness to IVIG.

【 授权许可】

CC BY